IL1B and COVID-19: By contrast, the dynamic of MIP-1β, IL-1β, MIP-1α and IFN-γ showed a different profile during the follow up, with significant higher levels at month 1 (IL-1β and IFN-γ) and month 3 (MIP-1β, IL-1β, MIP-1α and IFN-γ) among patients with mild/moderate diseases, compared to those with severe COVID-19.